FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
Publishing timestamp: 2024-06-10 17:08:08
Summary
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab for full approval in the U.S., potentially expanding treatment options for Alzheimer's patients. The drug would be the second of its kind on the market after Leqembi from Biogen and Eisai. Concerns remain about the need for more data on the drug's effectiveness in certain patient groups, as well as potential side effects such as brain swelling and bleeding.
Sentiment: MIXED
Keywords: biotech and pharmaceuticals, health care industry, biotechnology, business news, eli lilly and co, fda, science, pharmaceuticals, business,
Source: https://www.cnbc.com/2024/06/10/fda-advisors-recommend-eli-lilly-alzheimers-drug-donanemab.html